Collaborations and Other Relationships - Additional Information (Details) - USD ($)		3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 04, 2020	Jul. 04, 2021	Jun. 28, 2020	Jul. 04, 2021	Jun. 28, 2020	Jan. 03, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development expense		$ 30,400,000	$ 25,800,000	$ 59,300,000	$ 49,400,000
Joint Business | Grifols Diagnostic Solutions, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Net profit shared under joint venture, before tax		13,400,000	9,900,000	24,200,000	22,500,000
Letter Agreement | Quotient Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable upfront payment	$ 7,500,000
Research and development expense						$ 7,500,000
Inventories, purchased		$ 6,500,000	$ 5,300,000	$ 12,000,000.0	$ 10,700,000
Letter Agreement | Quotient Limited | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential additional payments upon achievement of certain regulatory milestones and commercial sales benchmarks	60,000,000.0
Potential payments upon achievement of certain cumulative revenue milestones	$ 25,000,000.0